ImmunityBio (IBRX) Capital Expenditures (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.68% |
| Dec 31, 2025 | -44.91% |
| Sep 30, 2025 | 25.69% |
| Dec 31, 2024 | -271.10% |
| Sep 30, 2024 | 285.64% |
| Jun 30, 2024 | -42.59% |
| Mar 31, 2024 | -84.15% |
| Dec 31, 2023 | -25.21% |
| Sep 30, 2023 | 251.07% |
| Jun 30, 2023 | -136.99% |
| Mar 31, 2023 | 8,396.88% |
| Dec 31, 2022 | 122.74% |
| Sep 30, 2022 | -107.95% |
| Jun 30, 2022 | 1,068.05% |
| Mar 31, 2022 | 109.22% |
| Dec 31, 2021 | -177.68% |
| Sep 30, 2021 | 263.06% |
| Jun 30, 2021 | -4.38% |
| Mar 31, 2021 | 710.44% |
| Jun 30, 2020 | 445.23% |
| Mar 31, 2020 | -53.25% |
| Dec 31, 2019 | -64.22% |
| Sep 30, 2019 | 403.46% |
| Jun 30, 2019 | -135.60% |
| Mar 31, 2019 | 131.77% |
| Dec 31, 2018 | -274.53% |
| Sep 30, 2018 | 46.99% |
| Jun 30, 2018 | -49.16% |
| Mar 31, 2018 | 135.31% |
| Dec 31, 2017 | -229.53% |
| Sep 30, 2017 | 31.40% |
| Jun 30, 2017 | 80.88% |
| Mar 31, 2017 | 232.03% |
| Dec 31, 2016 | -55.89% |
| Sep 30, 2016 | 191.57% |
| Jun 30, 2016 | -1.03% |
| Mar 31, 2016 | 11.73% |
| Dec 31, 2015 | -15.78% |
| Sep 30, 2015 | 894.74% |
| Jun 30, 2015 | 200.00% |
| Mar 31, 2015 | 2.70% |
| Dec 31, 2014 | -79.56% |